Impact of tacrolimus intra-patient variability in adverse outcomes after organ transplantation  

作　　者：Maria Clara Morais Maria Eduarda Soares Gabriela Costa Laura Guerra Nayana Vaz Liana Codes Paulo Lisboa Bittencourt 

机构地区：[1]School of Medicine,Bahiana School of Medicine and Public Health,Salvador 40290-000,Bahia,Brazil [2]School of Medicine,Federal University of Bahia,Salvador 40110-100,Bahia,Brazil [3]Unit of Gastroenterology and Hepatology,Portuguese Hospital,Salvador 40130-030,Bahia,Brazil

出　　处：《World Journal of Transplantation》2023年第5期254-263,共10页世界移植杂志

摘　　要：Tacrolimus(Tac)is currently the most common calcineurin-inhibitor employed in solid organ transplantation.High intra-patient variability(IPV)of Tac(Tac IPV)has been associated with an increased risk of immune-mediated rejection and poor outcomes after kidney transplantation.Few data are available concerning the impact of high Tac IPV in non-kidney transplants.However,even in kidney transplantation,there is still a controversy whether high Tac IPV is indeed detrimental in respect to graft and/or patient survival.This may be due to different methods employed to evaluate IPV and distinct time frames adopted to assess graft and patient survival in those reports published up to now in the literature.Little is also known about the influence of high Tac IPV in the development of other untoward adverse events,update of the current knowledge regarding the impact of Tac IPV in different outcomes following kidney,liver,heart,lung,and pancreas tran-splantation to better evaluate its use in clinical practice.

关 键 词：TACROLIMUS Intra-patient variability REJECTION Organ transplantation Graft survival OUTCOMES 

分 类 号：R18[医药卫生—流行病学]